Management of Localized Low-Grade Follicular Lymphoma

  • Neil B. Desai
  • Sarah A. MilgromEmail author


Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma. A long natural history and an evolution in staging modalities and treatment options has complicated studies regarding its optimal management. As a result, there is great variety in the therapeutic approaches used for low-grade (grade 1–2) early-stage FL. Definitive radiation therapy (RT) to a generous involved site volume to 24 Gy remains the recommended treatment for patients with stage I or contiguous stage II disease, based on retrospective data demonstrating prolonged disease-free intervals and even cure. An alternative is an even lower-dose RT to 4 Gy, which results in high response rates, with less toxicity but inferior local control. Additionally, observation may be appropriate in selected cases. The use of immunochemotherapy may improve progression-free survival (PFS) when added to RT but does not appear to affect overall survival, so its use in combination with RT or alone remains under investigation. This chapter review focuses on current understanding of these issues in localized grade 1–2 FL.


Follicular lymphoma FL Low-grade lymphoma Radiation therapy Radiotherapy Watch and wait Observation 


  1. 1.
    Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258–65.CrossRefGoogle Scholar
  2. 2.
    Friedberg JW, Taylor MD, Cerhan JR, Flowers CR, Dillon H, Farber CM, et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol. 2009;27(8):1202–8.CrossRefGoogle Scholar
  3. 3.
    Tsang RW, Gospodarowicz MK. Low-grade non-Hodgkin lymphomas. Semin Radiat Oncol. 2007;17(3):198–205.CrossRefGoogle Scholar
  4. 4.
    Friedberg JW, Byrtek M, Link BK, Flowers C, Taylor M, Hainsworth J, et al. Effectiveness of first-line management strategies for stage I follicular lymphoma: analysis of the National LymphoCare Study. J Clin Oncol. 2012;30(27):3368–75.CrossRefGoogle Scholar
  5. 5.
    Gospodarowicz MK, Bush RS, Brown TC, Chua T. Prognostic factors in nodular lymphomas: a multivariate analysis based on the Princess Margaret Hospital experience. Int J Radiat Oncol Biol Phys. 1984;10(4):489–97.CrossRefGoogle Scholar
  6. 6.
    Mac Manus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol. 1996;14(4):1282–90.CrossRefGoogle Scholar
  7. 7.
    Kamath SS, Marcus RB Jr, Lynch JW, Mendenhall NP. The impact of radiotherapy dose and other treatment-related and clinical factors on in-field control in stage I and II non-Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys. 1999;44(3):563–8.CrossRefGoogle Scholar
  8. 8.
    Guadagnolo BA, Li S, Neuberg D, Ng A, Hua L, Silver B, et al. Long-term outcome and mortality trends in early-stage, grade 1–2 follicular lymphoma treated with radiation therapy. Int J Radiat Oncol Biol Phys. 2006;64(3):928–34.CrossRefGoogle Scholar
  9. 9.
    Campbell BA, Voss N, Woods R, Gascoyne RD, Morris J, Pickles T, et al. Long-term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy. Cancer. 2010;116(16):3797–806.CrossRefGoogle Scholar
  10. 10.
    Brady JL, Binkley MS, Hajj C, Chelius MR, Chau KW, Levis M, et al. Outcome of curative radiotherapy for localised follicular lymphoma in the era of 18F-FDG PET-CT staging: an international collaborative study on behalf of ILROG. Hematol Oncol. 2017;35(S2):29–31.CrossRefGoogle Scholar
  11. 11.
    Lowry L, Smith P, Qian W, Falk S, Benstead K, Illidge T, et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol. 2011;100(1):86–92.CrossRefGoogle Scholar
  12. 12.
    Hoskin PJ, Kirkwood AA, Popova B, Smith P, Robinson M, Gallop-Evans E, et al. 4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial. Lancet Oncol. 2014;15(4):457–63.CrossRefGoogle Scholar
  13. 13.
    Fasola CE, Jones JC, Huang DD, Le QT, Hoppe RT, Donaldson SS. Low-dose radiation therapy (2 Gy x 2) in the treatment of orbital lymphoma. Int J Radiat Oncol Biol Phys. 2013;86(5):930–5.CrossRefGoogle Scholar
  14. 14.
    Pinnix CC, Dabaja BS, Milgrom SA, Smith GL, Abou Z, Nastoupil L, et al. Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. Head Neck. 2017;39(6):1095–100.CrossRefGoogle Scholar
  15. 15.
    Goda JS, Le LW, Lapperriere NJ, Millar BA, Payne D, Gospodarowicz MK, et al. Localized orbital mucosa-associated lymphoma tissue lymphoma managed with primary radiation therapy: efficacy and toxicity. Int J Radiat Oncol Biol Phys. 2011;81(4):e659–66.CrossRefGoogle Scholar
  16. 16.
    Illidge T, Specht L, Yahalom J, Aleman B, Berthelsen AK, Constine L, et al. Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2014;89(1):49–58.CrossRefGoogle Scholar
  17. 17.
    Seymour JF, Pro B, Fuller LM, Manning JT, Hagemeister FB, Romaguera J, et al. Long-term follow-up of a prospective study of combined modality therapy for stage I–II indolent non-Hodgkin’s lymphoma. J Clin Oncol. 2003;21(11):2115–22.CrossRefGoogle Scholar
  18. 18.
    Yahalom J, Varsos G, Fuks Z, Myers J, Clarkson BD, Straus DJ. Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma. Results of a prospective randomized study. Cancer. 1993;71(7):2342–50.CrossRefGoogle Scholar
  19. 19.
    Kelsey SM, Newland AC, Hudson GV, Jelliffe AM. A British National Lymphoma Investigation randomised trial of single agent chlorambucil plus radiotherapy versus radiotherapy alone in low grade, localised non-Hodgkins lymphoma. Med Oncol. 1994;11(1):19–25.CrossRefGoogle Scholar
  20. 20.
    Ruella M, Filippi AR, Bruna R, Di Russo A, Magni M, Caracciolo D, et al. Addition of rituximab to involved-field radiation therapy prolongs progression-free survival in stage I–II follicular lymphoma: results of a multicenter study. Int J Radiat Oncol Biol Phys. 2016;94(4):783–91.CrossRefGoogle Scholar
  21. 21.
    Janikova A, Bortlicek Z, Campr V, Kopalova N, Benesova K, Belada D, et al. Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of early-stage follicular lymphoma: is it time to change the standard strategy? Leuk Lymphoma. 2015;56(8):2350–6.CrossRefGoogle Scholar
  22. 22.
    Michallet AS, Lebras LL, Bauwens DD, Bouafia-Sauvy FF, Berger FF, Tychyj-Pinel CC, et al. Early stage follicular lymphoma: what is the clinical impact of the first-line treatment strategy? J Hematol Oncol. 2013;6:45.CrossRefGoogle Scholar
  23. 23.
    Mondello P, Steiner N, Wasle I, Pitini V, Mian M. Radiotherapy for stage I/II follicular lymphoma (FL): is it time for a re-appraisal? Anticancer Res. 2014;34(11):6701–4.PubMedGoogle Scholar
  24. 24.
    Barzenje DA, Cvancarova Smastuen M, Liestol K, Fossa A, Delabie J, Kolstad A, et al. Radiotherapy compared to other strategies in the treatment of stage I/II follicular lymphoma: a study of 404 patients with a median follow-up of 15 years. PLoS One. 2015;10(7):e0131158.CrossRefGoogle Scholar
  25. 25.
    Sancho JM, Garcia O, Mercadal S, Pomares H, Fernandez-Alvarez R, Gonzalez-Barca E, et al. The long term follow-up of early stage follicular lymphoma treated with radiotherapy, chemotherapy or combined modality treatment. Leuk Res. 2015;39(8):853–8.CrossRefGoogle Scholar
  26. 26.
    Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin’s lymphomas. N Engl J Med. 1984;311(23):1471–5.CrossRefGoogle Scholar
  27. 27.
    Pugh TJ, Ballonoff A, Newman F, Rabinovitch R. Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation: a surveillance, epidemiology, and end results database analysis. Cancer. 2010;116(16):3843–51.CrossRefGoogle Scholar
  28. 28.
    Soubeyran P, Eghbali H, Trojani M, Bonichon F, Richaud P, Hoerni B. Is there any place for a wait-and-see policy in stage I0 follicular lymphoma? A study of 43 consecutive patients in a single center. Ann Oncol. 1996;7(7):713–8.CrossRefGoogle Scholar
  29. 29.
    Solal-Celigny P, Bellei M, Marcheselli L, Pesce EA, Pileri S, McLaughlin P, et al. Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database. J Clin Oncol. 2012;30(31):3848–53.CrossRefGoogle Scholar
  30. 30.
    Yuda S, Maruyama D, Maeshima AM, Makita S, Kitahara H, Miyamoto KI, et al. Influence of the watch and wait strategy on clinical outcomes of patients with follicular lymphoma in the rituximab era. Ann Hematol. 2016;95(12):2017–22.CrossRefGoogle Scholar
  31. 31.
    Advani R, Rosenberg SA, Horning SJ. Stage I and II follicular non-Hodgkin’s lymphoma: long-term follow-up of no initial therapy. J Clin Oncol. 2004;22(8):1454–9.CrossRefGoogle Scholar
  32. 32.
    (NCCN) NCCN. NCCN Clinical practice guidelines in oncology. B-cell lymphomas version 5.2017. In: Network. NCC, editor. 2017.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.University of Texas Southwestern, Department of Radiation OncologyDallasUSA
  2. 2.MD Anderson Cancer Center, Department of Radiation OncologyHoustonUSA

Personalised recommendations